The anti-ERBB2 antibody, trastuzumab, was developed to treat ERBB2-positive breast cancer. The cardiac toxicity it produced was unexpected but led to new insights about a role for ERBB2 in the response of the heart to stress.
No takes yet. Share an insight, caveat, or question.
Coté et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: